Skip to main content

Jazz Pharmaceuticals to Showcase Growing Impact in Solid Tumor Oncology Research at ESMO 2023

PR Newswire - Mon Oct 16, 2023

Zanidatamab data demonstrate clinical potential of novel bispecific antibody in HER2-targeted biliary tract and gastric cancers

Additional presentations, including a lurbinectedin oral presentation in small cell lung cancer (SCLC), underscore the strength of Jazz's solid tumor portfolio and the company's commitment to address difficult-to-treat tumors

Read more at prnewswire.com

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.